Databean-Octapharma:Treatment registry study of IVIG

Investigator: Ahmed Gaber, MD

Study Coordinator: Alejandro De La Torre

Status: Enrolling

ClinicalTrials.gov Number: NCT02115503

Phone: 000.000.0000

IRB Number: Pro00010952

Description

The purpose of this treatment registry study is to determine if monthly infusions of Intravenous Immunoglobulin (IVIg) for 6 months will neutralize donor specific antibodies that are thought to be responsible for chronic rejection episodes in renal transplant subjects. 162 renal transplant subjects will receive IVIg 5% at 2gm/kg/month for 6 months and be followed for 3 years.
More to Explore